NASDAQ:ANIK Anika Therapeutics (ANIK) Stock Price, News & Analysis $27.90 -0.41 (-1.45%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$27.51▼$28.5950-Day Range$24.57▼$28.7552-Week Range$16.54▼$29.11Volume38,780 shsAverage Volume68,232 shsMarket Capitalization$407.06 millionP/E RatioN/ADividend YieldN/APrice Target$30.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Anika Therapeutics alerts: Email Address Anika Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside9.3% Upside$30.50 Price TargetShort InterestBearish4.96% of Float Sold ShortDividend StrengthN/ASustainability-2.12Upright™ Environmental ScoreNews Sentiment0.50Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.05) to $0.10 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.30 out of 5 starsMedical Sector573rd out of 936 stocksSurgical & Medical Instruments Industry71st out of 101 stocks 1.3 Analyst's Opinion Consensus RatingAnika Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAnika Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Anika Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.96% of the float of Anika Therapeutics has been sold short.Short Interest Ratio / Days to CoverAnika Therapeutics has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.Change versus previous monthShort interest in Anika Therapeutics has recently decreased by 2.86%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAnika Therapeutics does not currently pay a dividend.Dividend GrowthAnika Therapeutics does not have a long track record of dividend growth. Previous Next 3.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAnika Therapeutics has received a 43.44% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic bone grafts", "Medical splints", and "Medical screws" products. See details.Environmental SustainabilityThe Environmental Impact score for Anika Therapeutics is -2.12. Previous Next 3.1 News and Social Media Coverage News SentimentAnika Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Anika Therapeutics this week, compared to 1 article on an average week.Search Interest5 people have searched for ANIK on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Anika Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anika Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.86% of the stock of Anika Therapeutics is held by insiders.Percentage Held by Institutions91.53% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Anika Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Anika Therapeutics are expected to grow in the coming year, from ($0.05) to $0.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anika Therapeutics is -5.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anika Therapeutics is -5.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnika Therapeutics has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Anika Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Anika Therapeutics Stock (NASDAQ:ANIK)Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.Read More ANIK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANIK Stock News HeadlinesJuly 25 at 9:11 PM | msn.comViking Therapeutics stock jumps nearly 30% after drugmaker moves weight loss injection to late-stage trialJuly 25 at 4:09 PM | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Option Care Health (OPCH), Edwards Lifesciences (EW)July 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 25 at 9:00 AM | globenewswire.comAnika to Issue Second Quarter 2024 Financial Results on Thursday, August 8, 2024July 23, 2024 | finance.yahoo.comWe're Not Worried About Anika Therapeutics' (NASDAQ:ANIK) Cash BurnJuly 22, 2024 | americanbankingnews.comContrasting Biotricity (NASDAQ:BTCY) & Anika Therapeutics (NASDAQ:ANIK)July 18, 2024 | americanbankingnews.comAnika Therapeutics (NASDAQ:ANIK) Stock Crosses Above 200-Day Moving Average of $25.17July 16, 2024 | globenewswire.comAnika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 11, 2024 | globenewswire.comAnika Announces Full Market Release of the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon RepairsJuly 1, 2024 | globenewswire.comOrthopedic Regenerative Surgical Products Market Size to Reach USD 6.6 Billion By 2033, at 4.4 CAGR: Insights by Dimension Market ResearchJune 7, 2024 | globenewswire.comAnika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 29, 2024 | benzinga.comPeeling Back The Layers: Exploring Anika Therapeutics Through Analyst InsightsMay 28, 2024 | marketwatch.comAnika Therapeutics Agrees to Board Appointments, Buybacks In Deal With ShareholderMay 28, 2024 | globenewswire.comAnika Enters into Cooperation Agreement with Caligan PartnersMay 16, 2024 | finance.yahoo.comPendopharm renews distribution agreement with Anika Therapeutics Inc. for Cingal®, Monovisc®, and Orthovisc®May 10, 2024 | finance.yahoo.comAnika Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 10, 2024 | finanznachrichten.deAnika Therapeutics Inc.: Anika Announces CFO TransitionSee More Headlines Receive ANIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/27/2024Next Earnings (Confirmed)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:ANIK CUSIP03525510 CIK898437 Webwww.anikatherapeutics.com Phone(781) 457-9000Fax781-305-9720Employees300Year Founded1992Price Target and Rating Average Stock Price Target$30.50 High Stock Price Target$37.00 Low Stock Price Target$24.00 Potential Upside/Downside+9.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($5.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,670,000.00 Net Margins-45.39% Pretax Margin-45.96% Return on Equity0.48% Return on Assets0.39% Debt Debt-to-Equity RatioN/A Current Ratio5.59 Quick Ratio3.85 Sales & Book Value Annual Sales$166.66 million Price / Sales2.44 Cash Flow$4.89 per share Price / Cash Flow5.70 Book Value$14.50 per share Price / Book1.92Miscellaneous Outstanding Shares14,590,000Free Float13,440,000Market Cap$407.06 million OptionableOptionable Beta0.83 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Cheryl Renee Blanchard Ph.D. (Age 60)President, CEO & Director Comp: $1.34MMr. Michael L. Levitz (Age 50)Executive VP, CFO & Treasurer Comp: $734.14kMr. Ian W. McLeodVP & Chief Accounting OfficerMr. Mark Namaroff (Age 61)Executive Director of Investor Relations & Corporate Communications Mr. James ChaseSenior Vice President of International Sales & MarketingMr. Ben JosephVice President of Commercial & Corporate DevelopmentMs. Lisa FunicielloVice President of Human ResourcesMore ExecutivesKey CompetitorsAccurayNASDAQ:ARAYVapothermNYSE:VAPOAtrionNASDAQ:ATRICerusNASDAQ:CERSOraSure TechnologiesNASDAQ:OSURView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 10,439 shares on 7/26/2024Ownership: 0.421%Allspring Global Investments Holdings LLCSold 6,908 shares on 7/26/2024Ownership: 0.400%Riverwater Partners LLCSold 1,703 shares on 7/19/2024Ownership: 0.109%SG Americas Securities LLCSold 1,988 shares on 7/12/2024Ownership: 0.045%Boston PartnersBought 28,852 shares on 5/28/2024Ownership: 0.195%View All Institutional Transactions ANIK Stock Analysis - Frequently Asked Questions How have ANIK shares performed this year? Anika Therapeutics' stock was trading at $22.66 at the start of the year. Since then, ANIK shares have increased by 23.1% and is now trading at $27.90. View the best growth stocks for 2024 here. How were Anika Therapeutics' earnings last quarter? Anika Therapeutics, Inc. (NASDAQ:ANIK) posted its quarterly earnings data on Wednesday, May, 8th. The biotechnology company reported $0.09 EPS for the quarter, missing analysts' consensus estimates of $0.13 by $0.04. The biotechnology company had revenue of $40.52 million for the quarter, compared to analyst estimates of $39.23 million. Anika Therapeutics had a negative net margin of 45.39% and a positive trailing twelve-month return on equity of 0.48%. Who are Anika Therapeutics' major shareholders? Anika Therapeutics' top institutional investors include Bank of New York Mellon Corp (0.42%), Allspring Global Investments Holdings LLC (0.40%), Riverwater Partners LLC (0.11%) and SG Americas Securities LLC (0.05%). Insiders that own company stock include David Colleran, Cheryl R Blanchard, Jeffery S Thompson and Michael L Levitz. View institutional ownership trends. How do I buy shares of Anika Therapeutics? Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Anika Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA) and Advanced Micro Devices (AMD). This page (NASDAQ:ANIK) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anika Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anika Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.